Abstract:Cancer remains a serious health concern representing one of the leading causes of deaths worldwide. The enzyme human carbonic anhydrase IX (hCA IX) is found to be over-expressed in many cancer types and its selective inhibition over its cytosolic off-target isoform, human carbonic anhydrase II (hCA II), represents a potential area of research in the development of novel anticancer compounds. This work is concerned with the use of various in silico tools for the identification of natural product based molecules that can selectively inhibit hCA IX over hCA II. MM-GBSA assisted structure-based virtual screening against hCA IX was performed for nearly 225,000 natural products imported from the ZINC15 database. The obtained hits were checked for their potency by considering acetazolamide, the bound inhibitor of hCA IX, as the reference molecule, and 121 molecules were identified as potent hCA IX inhibitors. After ensuring their potency, cross-docking, followed by MM-GBSA calculations of the hits with hCA II, was performed, and their selectivity was assessed by considering the hCA IX selective compound SLC-0111 as the reference molecule, and 50 natural products were identified as potent as well as selective hCA IX inhibitors. Molecules with the quinoline scaffold showed the highest selectivity, and their selectivity was attributed to the strong electrostatic interactions of the zinc binding group (ZBG) with the active site Zn(II) ion. Furthermore, the stability of the binding modes of the top hCA IX selective hits was ensured by performing molecular dynamics (MD) simulations, which clearly proved that one of the short-listed molecules is truly selective, as it does not interact with the active site Zn(II) ion of hCA II, but interacts strongly with this ion in hCA IX. Bonding pose metadynamics studies revealed that the ligand moves to a more stable binding site from the one predicted by the docking studies and shows stronger interaction with the protein and Zn(II) at this binding site. The ligand is not likely to have issues with bioavailability. As a result, this ligand can be taken for bioassay testing and subsequently used as a feasible therapeutic treatment for a variety of cancer types. Communicated by Ramaswamy H. Sarma

Structure-Guided Design of C3-Branched Swainsonine as Potent and Selective Human Golgi α-Mannosidase (GMII) Inhibitor

Identification of a potential allosteric site of Golgi α-mannosidase II using computer-aided drug design

Biosynthesis of the α-D-Mannosidase Inhibitor (-)-Swainsonine

Biosynthesis of the alpha-D-Mannosidase Inhibitor (-)-Swainsonine

Synthesis of α‐Hydroxy‐1,2,3‐Triazole‐linked Sialyltransferase Inhibitors and Evaluation of Selectivity Towards ST3GAL1, ST6GAL1 and ST8SIA2

Gramine-based structure optimization to enhance anti-gastric cancer activity

A Computational and Chemical Design Strategy for Manipulating Glycan‐Protein Recognition

Synthesis and Biological Evaluation of Novel Spin Labeled 18Β-Glycyrrhetinic Acid Derivatives

Protein Degradation via CRL4 CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

A crystal structure-guided rational design switching non-carbohydrate inhibitors' specificity between two β-GlcNAcase homologs

Virtual screening, identification and in vitro validation of small molecule GDP-mannose dehydrogenase inhibitors

Identification of benzothiazole derived monosaccharides as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3; a rare example of using a S···O binding interaction for drug design

In silico–guided synthesis of a new, highly soluble, and anti‐melanoma flavone glucoside: Skullcapflavone II‐6′‐O‐β‐glucoside

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

A combination strategy of structure-based virtual screening, MM-GBSA, cross docking, molecular dynamics and metadynamics simulations used to investigate natural compounds as potent and specific inhibitors of tumor linked human carbonic anhydrase IX

DDIS-04. COMPOUNDS IDENTIFIED BY STRUCTURE BASED VIRTUAL SCREENING DECREASE GBM BTIC GROWTH AND GLUCOSE UPTAKE

Structure-based Design, Synthesis and Bioactivity Evaluation of Macrocyclic Inhibitors of Mutant Isocitrate Dehydrogenase 2 (IDH2) Displaying Activity in Acute Myeloid Leukemia Cells.

Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site

Enhancing structural diversity through chemical engineering of Ambrosia tenuifolia extract for novel anti-glioblastoma compounds

Structure‐guided engineering of key amino acids in UGT85B1 controlling substrate and stereo‐specificity in aromatic cyanogenic glucoside biosynthesis

Structure-guided engineering of the substrate specificity of a fungal β-glucuronidase toward triterpenoid saponins